Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study

The Lancet

Volumn 394, Issue 10195, 2019, Pages 332-343

  Battle, Katherine E ^a   Lucas, Tim C D ^a   Nguyen, Michele ^a   Howes, Rosalind E ^a   Nandi, Anita K ^a   Twohig, Katherine A ^a   Pfeffer, Daniel A ^b   Cameron, Ewan ^a   Rao, Puja C ^h   Casey, Daniel ^c   Gibson, Harry S ^a   Rozier, Jennifer A ^a   Dalrymple, Ursula ^d   Keddie, Suzanne H ^a   Collins, Emma L ^a   Harris, Joseph R ^a   Guerra, Carlos A ^e   Thorn, Michael P ^a   Bisanzio, D ^f,g   Fullman, N ^h   Huynh, Chantal K ^h   Kulikoff, Xie ^h   Kutz, Michael J ^h   Lopez, Alan D ^h   Mokdad, A H ^h   Naghavi, Mohsen ^h   Nguyen, G ^h   Shackelford, Katya Anne ^h   Vos, Theo ^h   Wang, Haidong ^h   Lim, Stephen S ^h   Murray, Christopher J L ^h   Price, R N ^a,b   Baird, J Kevin ^a,i   Smith, David L ^h   Bhatt, S ^j   Weiss, Daniel J ^a   Hay, Simon I ^h   Gething, Peter W ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c Public Health Seattle King County   (United States)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Medical Care Development International   (United States)

^f RTI INTERNATIONAL   (United States)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ Eijkman Oxford Clinical Research Unit   (Indonesia)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFGHANISTAN; AFRICA SOUTH OF THE SAHARA; ARTICLE; BAYES THEOREM; BRAZIL; CHINA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE BURDEN; DISEASE SURVEILLANCE; DJIBOUTI; ENDEMIC DISEASE; ETHIOPIA; GLOBAL DISEASE BURDEN; GUYANA; HUMAN; INCIDENCE; INDIA; INDONESIA; INFECTION RATE; MAJOR CLINICAL STUDY; MEXICO; PAKISTAN; PAPUA NEW GUINEA; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PREVALENCE; PRIORITY JOURNAL; SOLOMON ISLANDS; SUDAN; VANUATU; VENEZUELA; YEMEN; AFRICA; GLOBAL HEALTH; HEALTH SURVEY; PACIFIC ISLANDS; SOUTHEAST ASIA; SPATIOTEMPORAL ANALYSIS; STATISTICS AND NUMERICAL DATA; WESTERN HEMISPHERE;

AFRICA; AMERICAS; ASIA, SOUTHEASTERN; BAYES THEOREM; ENDEMIC DISEASES; GLOBAL HEALTH; HUMANS; MALARIA, VIVAX; OCEANIA; POPULATION SURVEILLANCE; SPATIO-TEMPORAL ANALYSIS;

EID: 85069656234     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)31096-7     Document Type: Article

References (44)

1. Cibulskis, RE, Alonso, P, Aponte, J, et al. Malaria: global progress 2000–2015 and future challenges. Infect Dis Poverty, 5, 2016, 61.
2. Gates, B, Chambers, R, From Aspiration to Action. http://endmalaria2040.org/, 2015. (Accessed 1 August 2018)
3. Lover, AA, Baird, JK, Gosling, R, Price, RN, Malaria elimination: time to target all species. Am J Trop Med Hyg 99 (2018), 17–23.
4. Baird, JK, Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 26 (2013), 36–57.
5. Poespoprodjo, JR, Fobia, W, Kenangalem, E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 48 (2009), 1704–1712.
6. WHO. Guidelines for the Treatment of Malaria, Third Edition. Geneva, Switzerland: World Health Organization. https://www.who.int/malaria/publications/atoz/9789241549127/en/, 2015. (Accessed 1 August 2018)
7. Thriemer, K, Bobogare, A, Ley, B, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J, 17, 2018, 241.
8. Baird, J, Louisa, M, Noviyanti, R, et al. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Network Open, 1, 2018, e181449.
9. Baird, JK, Battle, KE, Howes, RE, Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. Malar J, 17, 2018, 42.
10. Mendis, K, Sina, BJ, Marchesini, P, Carter, R, The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64:suppl 1–2 (2001), 97–106.
11. Hay, SI, Guerra, CA, Tatem, AJ, Noor, AM, Snow, RW, The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 4 (2004), 327–336.
12. Price, RN, Tjitra, E, Guerra, CA, Yeung, S, White, NJ, Anstey, NM, Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77:suppl 6 (2007), 79–87.
13. Lysenko, AJ, Semashko, IN, Geography of malaria. A medico-geographic profile of an ancient disease. Lebedew, AW, (eds.) Itogi Nauki: Medicinskaja Geografija, 1968, Academy of Sciences, Moscow, USSR, 25–146.
14. WHO. World Malaria Report 2014. Geneva, Switzerland: World Health Organization. https://www.who.int/malaria/publications/world_malaria_report_2014/en/, 2014. (Accessed 1 August 2018)
15. Mueller, I, Galinski, MR, Baird, JK, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9 (2009), 555–566.
16. Gething, PW, Elyazar, IR, Moyes, CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis, 6, 2012, e1814.
17. Weiss, DJ, Lucas, TCD, Nguyen, M, et al. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal modelling study. Lancet, 2019 published online June 19. http://dx.doi.org/10.1016/S0140-6736(19)31097-9.
18. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 355 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 382 (2018), 1789–1858.
19. Battle, KE, Cameron, E, Guerra, CA, et al. Defining the relationship between Plasmodium vivax parasite rate and clinical disease. Malar J, 14, 2015, 191.
20. Twohig, KA, Pfeffer, DA, Baird, JK, et al. Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLoS Negl Trop Dis, 13, 2019, e0007140.
21. Miller, LH, Mason, SJ, Clyde, DF, McGinniss, MH, The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295 (1976), 302–304.
22. Malaria Indicator Surveys. Roll Back Malaria. http://www.malariasurveys.org/, 2015. (Accessed 22 June 2015)
23. USAID. The DHS Program. http://www.dhsprogram.com/, 2017. (Accessed 28 July 2017)
24. Bhatt, S, Weiss, DJ, Cameron, E, et al. The effect of malaria control on Plasmodium falciparum in Africa, 2000–2015. Nature 526 (2015), 207–211.
25. Cameron, E, Battle, KE, Bhatt, S, et al. Defining the relationship between infection prevalence and clinical incidence of Plasmodium falciparum malaria. Nat Commun, 6, 2015, 8170.
26. WHO. World Malaria Report 2017. Geneva, Switzerland: World Health Organization. https://www.who.int/malaria/publications/world-malaria-report-2017/en/, 2017. (Accessed 31 May 2019)
27. WHO. World Malaria Report 2008. Geneva, Switzerland: World Health Organization. https://www.who.int/malaria/publications/atoz/9789241563697/en/, 2008. (Accessed 10 January 2015)
28. Cibulskis, RE, Aregawi, M, Williams, R, Otten, M, Dye, C, Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods. PLoS Med, 8, 2011, e1001142.
29. WHO. World Malaria Report 2015. Geneva, Switzerland: World Health Organization. https://www.who.int/malaria/publications/world-malaria-report-2015/report/en/, 2015. (Accessed 1 August 2018)
30. Deressa, W, Treatment-seeking behaviour for febrile illness in an area of seasonal malaria transmission in rural Ethiopia. Malar J, 6, 2007, 49.
31. Howes, RE, Reiner, RC Jr, Battle, KE, et al. Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis, 9, 2015, e0004222.
32. Howes, RE, Patil, AP, Piel, FB, et al. The global distribution of the Duffy blood group. Nat Commun, 2, 2011, 266.
33. Pfeffer, DA, Lucas, TCD, May, D, et al. malariaAtlas: an R interface to global malariometric data hosted by the Malaria Atlas Project. Malar J, 17, 2018, 352.
34. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) Population Estimates 1950–2016, 2017, Institute for Health Metrics and Evaluation, Seattle, United States.
35. The World Bank. Data: indicators. http://data.worldbank.org/indicator/all, 2017. (Accessed 23 June 2017)
36. Li, Y, Brown, P, Gesink, DC, Rue, H, Log Gaussian Cox processes and spatially aggregated disease incidence data. Stat Methods Med Res 21 (2012), 479–507.
37. Sturrock, HJ, Cohen, JM, Keil, P, et al. Fine-scale malaria risk mapping from routine aggregated case data. Malar J, 13, 2014, 421.
38. Guerra, CA, Howes, RE, Patil, AP, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis, 4, 2010, e774.
39. Battle, KE, Guerra, CA, Golding, N, et al. Global database of matched Plasmodium falciparum and P vivax incidence and prevalence records from 1985–2013. Scientific Data, 2, 2015, 150012.
40. Battle, KE, Karhunen, MS, Bhatt, S, et al. Geographical variation in Plasmodium vivax relapse. Malar J, 13, 2014, 144.
41. Bousema, T, Okell, L, Felger, I, Drakeley, C, Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat Rev Microbiol 12 (2014), 833–840.
42. Galactionova, K, Tediosi, F, de Savigny, D, Smith, T, Tanner, M, Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries. PLoS One, 10, 2015, e0127818.
43. Obaldia, N 3rd, Meibalan, E, Sa, JM, et al. Bone marrow is a major parasite reservoir in Plasmodium vivax infection. MBio, 9, 2018, 33.
44. Chu, CS, White, NJ, Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther 14 (2016), 885–900.